Issue link: https://www.e-digitaleditions.com/i/701238
6 July 2016 Tablets & Capsules markets Global market for empty capsules to grow 7.2 percent annually PUNE, INDIA—The global mar- ket for empty capsules is forecast to increase from $1.5 billion in 2016 to $2.21 billion in 2021, a compound annual growth rate of 7.2 percent, according to a report from Markets- andMarkets. The factors driving mar- ket growth include an increasingly older population, more use of capsules in pharmaceutical and nutraceutical industries, and growing consumer preference towards capsule-based for- mulations. The report identifies ACG Worldwide, Capsugel, CapsCanada, Qualicaps, Suheung, Medi-Caps, Roxlor, Bright Pharma Caps, Snail Pharma, and Sunil as key players in the market. Latin American excipients market forecast to exceed $626 million by 2023 ALBANY, NY—A report by Trans- parency Market Research forecasts that the Latin American excipients market will reach $626.9 million in 2023, growing at a compound annual rate of 6.4 percent. South America dominated the excipients market in the region due to high demand from Brazil, Argentina, and Colombia. In 2014, polymers account- ed for the largest share of the market, led by an increase in demand for disin- tegrants and binders. Growth factors for the excipient market in the region include increasing consumption of oral solid dosage drug products and growth of the overall pharmaceutical market. industry news Perrigo to sell supplements business to International Vitamin DUBLIN, IRELAND—Perrigo agreed to sell its US vitamins, miner- als, and supplements (VMS) business to International Vitamin. The transac- tion is expected to close in early August. More than 300 people are employed in the VMS business. Perrigo is the world's largest manufac- turer of OTC healthcare products. CPhI to debut in USA, co-locate with Informex LONDON, UK—UBM is expand- ing its CPhI event to North America and will co-locate its debut with Informex May 16-18, 2017, in Philadelphia, PA. CPhI, which is dedi- cated to pharmaceutical ingredients, is offered in several other locations, including Europe, India, Japan, and China. It frequently also includes P- Mec, ICSE, InnoPack, and FDF. Those events focus on mechanical processing, contract development and manufactur- ing, packaging, and finished dosage forms. Informex is dedicated to several sectors of the chemical industry. Impax to acquire Teva generics HAYWARD, CA—Impax Labora- tories has agreed to acquire several generic products from Teva and affili- ates of Allergan. It will also be returned its rights to a pending ANDA for a generic equivalent of Concerta (methylphenidate hydrochloride), a Johnson & Johnson product. The deal is valued at $586 million. IPEC-Americas publishes QbD sampling guide for excipients, launches e-learning ARLINGTON, VA—IPEC-Ameri- cas published "Quality by Design Sampling Guide for Excipient Makers, Users, and Distributors." The guide recommends options for QbD sam- ples; offers advice on developing more robust pharmaceutical products and procedures; provideds tips on commu- nication between pharmaceutical man- ufacturers and and excipient manufac- turers; and outlines user and excipient supplier responsibilities. The guide is available as a free download at IPEC- America's website: http://bit.ly/QbD sample. In other news, IPEC-Americas has launched e-learning courses. It will begin with "Level 1—Excipient GMPs for Manufacturing Workers." The 2- hour course will cover the what and why of GMP, excipient functionality, documents and records, hygienic prac- tices, work environment, and relevance of GMP to production and plant main- tenance workers. It can be accessed on any internet-capable computer or mobile device anytime during the 14- day licensed access period. The group plans to offer similar courses for labora- tory workers, including production workers who perform in-process test- ing, QC technicians, and warehouse workers. Reformulated tablets could be factor in injuries, deaths from airbags NEW YORK, NY—Faulty airbags manufactured by Japanese supplier Takata resulted in the largest recall in automotive history and appear to be the cause of several injuries and deaths. According to a June 2 Bloomberg report, "Sixty million car bombs: Inside Takata's air bag crisis," the source of the problem is likely reformulated propel- lant tablets that generate the inflating gas. The report states that Takata replaced its tetrazole tablets with tablets made from ammonium nitrate, which became unstable after long-term exposure to temperature and moisture changes. That caused the tablets to break down into a powder that burned more quickly and caused the airbags explode and send metal shrapnel into the vehicle's cabin. The company is under criminal investigation by the US Department of Justice. FDA addresses chewable tablets SILVER SPRINGS, MD—The FDA issued a draft "Guidance for Industry: Quality Attribute Considerations for Chewable Tablets." It notes that the tablets should be easy to chew, palat- able, have an appropriate size and shape, and show disintegration charac- teristics that minimize the risk of aspi- ration and promote dissolution. The draft Guidance encourages formulators to address these issues early in devel- opment.. FDA targets more than 4,000 websites for illegal distribution of prescription drug products SILVER SPRING, MD—The FDA and other international regulators requested the suspension of 4,402 websites that sell illegal and counter- feit products to US customers. The Agency conducted several inspections